The possible involvement of a deficit of GH and insulin-like growth factor-I (somatomedin C) ( 
provide evidence that the GH treatment employed in the present experiments was adequate to restore the deficit. GH treatment had no significant effect on tail length or CNP activity, and only a small (4\p=n-\24%) effect on body weight at 20 days. Only thyroxine was able fully to restore body weight and substantially restore tail length and CNP activity.
The present study provides strong evidence against an important involvement of GH or IGF-I/SMC in mediating the effects of thyroid hormone on myelination and body growth in the infant rat. It does not, however, rule out the possibility that thyroid hormone is required for the expression of the growth-promoting effects of IGF-I/SMC by other mechanisms such as the expression of the IGF-I/SMC receptor. INTRODUCTION The extent to which growth hormone (GH) mediates the effects of thyroid hormone on body growth and brain development has been widely studied in juvenile rats. However, there have been few studies in the infant rat. In particular, there is conflicting infor¬ mation regarding the first 3 weeks after birth, an important period of brain development and rapid growth in this species, and a period during which some evidence suggests that the hormonal require¬ ments for growth may be different from those of older animals (Walker, Simpson, Ashling & Evans, 1950; Glasscock & Nicoli, 1981) .
With regard to the effects of GH on growth in the infant rat, Geel and Timiras (1970) demonstrated only a small response at 20 days of age following treatment of rats which had been thyroidectomized on day 1. In contrast, Krawiec, Garcia Argiz, Gomez & Pasquini (1969) showed a substantial growth response at 20 days of age in rats which had been radiothyroidectomized at birth and treated with bovine GH (bGH) from day 10. On the basis that this response was greater than that obtained with tri-iodothyronine (T3), these workers concluded that the failure of growth was an indirect effect of thyroid hormone deficit acting through a lack of GH. In another study, the effect of propylthiouracil (PTU)-induced hypothyroidism on growth and plasma concentrations of GH and insulin-like growth factor (IGF) was exam¬ ined in neonatal rats (Burnstein, Drazin, Johnson & Schalch, 1979) . Although decreased levels of GH and insulin-like growth factors (somatomedins) (IGF/SM) were shown to accompany growth retardation in their infant rats, the effects of GH treatment were studied only in adult animals where no effect on plasma IGF/ SM could be demonstrated. On this basis they con¬ cluded that thyroid hormone may have a direct effect on IGF/SM synthesis and/or release.
With regard to the effects of GH on myelination, a number of recent studies using cultured brain cells have reported stimulatory effects of either GH (Almazan, Honegger, Matthieu & Guentert-Lauber, 1985) or insu¬ lin-like growth factor-I (somatomedin C) (IGF-I/ SMC) (Lenoir & Honegger, 1983; McMorris, Smith, DeSalvo & Furlanetto, 1986) (King, Smith & Dreosti, 1983 Daughaday, Mariz & Blethen (1980) to remove binding protein.
Assays for GH
Pituitary extracts and plasma were assayed for GH by a double-antibody method using a kit supplied by the NIADDK (lot rGH-I-4 for iodination, lot rGH-RP-1 for reference preparation and antibody anti-rGH-S-4). The hormone was iodinated with Na125I (Amersham International pic, Bucks, U.K.) in NaP04 (0-5 mol/1), pH 7-6, by the 'iodogen' method (Pierce Chemical Company, Rockford, IL, U.S.A.). 125I-Labelled rGH was separated from free iodine on a DEAE A-25 Sephadex column and the peak fraction of radioactivity stored at -80°C in buffer (004mol NaP04/l, 001 mol EDTA/1, pH 7-6, containing 2-5 g BSA/1) and used within 1 week. Each assay tube contained 005ml sample (plasma or pituitary extract), 0-25 ml assay buffer A (0-01 mol NaPCyi, 0-025 mol EDTA/1, pH 7-6, con¬ taining 8-8 g NaCl, 1 g NaN3 and 1 g BSA/1), 0-1 ml l25I-labelled rGH in assay buffer A and 0-1 ml anti¬ body Assays for CNP Portions of the same crushed brain samples from experiment three that were used for extraction of IGF-I/SMC were also used for measurement of CNP activity. Homogenates were prepared in ice-cold dis¬ tilled water and treated with sodium deoxycholate as described by Kurihara & Takahashi (1979) . Enzyme activity was measured by their colorimetrie method using adenosine 2',3'monophosphate as substrate (Kurihara & Takahashi, 1979 Fig. 3 . In this experiment control litters were culled to either two or eight pups, but since there was no significant effect of litter size on the growth pattern of the pups, the data were combined for Fig. 3 (body weight at 20 days, 40-4 ± 0-6 g (s.e.m.) (« = 6) for litters of two, 390+1-4 (n = l) for litters of eight). Similarly there was no significant difference between the growth patterns of the untreated hypothyroid littermates of rGH-and thyroxine-treated pups, and these data were therefore also combined. figure 2. Effect of maternal propylthiouracil (PTU) treat¬ ment on (a) liver, (b) plasma and (c) brain concentration of insulin-like growth factor-I (somatomedin C) (IGF-I/SMC) in fetuses and pups. Livers and plasma from 8-12 fetuses from each mother were pooled, whereas postnatal samples were from individual pups (each from a separate litter). PTU-treated (rGH) or thyroxine (T4) on the concentration of insulin-like growth factor-I (somatomedin C) (IGF-I/SMC) in plasma, liver, kidney and brain, and on the activity of 2',3'-cyclic nucleotide 3'-phosphohydolase (CNP) (Mosier, Dearden, Jansons & Hill, 1977; Burnstein et al. 1979; Corio, Braverman, Christianson et al. 1979; Walker & Dussault, 1980) and plasma IGF-I/ SMC (Burnstein et al. 1979; Chernausek, Underwood & Van Wyk, 1982) accompanying growth retardation in hypothyroid rats. The present study extends these observations to show that the concentration of IGF-I/SMC in the kidney and liver, a major source of IGF-I/SMC, is also markedly reduced in the neonatal hypothyroid rat.
There is now strong evidence that the growthpromoting effects of GH are brought about through the binding of the hormone to its cell surface receptor, followed by production of IGF-I/SMC (Schoenle, Zapf, Hauri et al. 1985) . The ability of our hypo¬ thyroid rats to respond to GH administration with restoration of plasma, liver and kidney IGF-I/SMC levels indicates that GH receptors which develop during the neonatal period (Maes, De Hertogh, Watrin-Granger & Ketelslegers, 1983) remain func¬ tional in these animals, and that the dose of GH employed was adequate to replace the hypothyroid deficit. The lack of restoration of growth is, there¬ fore, clearly not due to a defect at the level of the GH receptor. This is consistent with another study in juvenile rats which showed no depletion of GH recep¬ tors in the livers of thyroidectomized animals and the restoration of plasma IGF-I/SMC levels towards nor¬ mal values following treatment with human GH (Chernausek et al. 1982 (Walker et al. 1950 ; Glasscock & Nicoli, 1981) .
In the present study, rGH treatment led to the res¬ toration of plasma IGF-I/SMC levels in hypothyroid animals to values higher than those of T4-treated or normal animals but this was not accompanied by any significant increase in skeletal growth as assessed by tail length, and had only a small (4-24%) effect on body weight. In addition, GH-treated pups retained their cretinoid characteristics including delayed eye opening, foreshortened snout and poorly developed ears, as reported by others (Scow, Simpson, Asling et al. 1949; Geel & Timiras, 1970 A number of other studies have examined the effects of GH administration on body growth of rats which had been thyroidectomized at birth. Only two have been concerned with the early postnatal period when hormonal requirements for growth may be dif¬ ferent from those of the juvenile and later periods (Walker et al. 1950 ; Glasscock & Nicoli, 1981 ). The results from those studies have, however, been con¬ flicting. Thus although Salmon (1941) (Scow & Marx, 1945; Scow et al. 1949; Ray, Simpson, Li et al. 1950) . In studies like the present ones using younger animals, Geel & Timiras (1970) showed only a small effect on body weight at 20 days following GH treat¬ ment from day 6, but Krawiec et al. (1969) showed a substantial response following treatment only between days 10 and 19. These latter results are puzzling since, even though the dose of GH employed in that study was substantially less than that used in the present work and by Geel & Timiras (1970) , the growth response with GH was greater than that obtained with thyroid hormone.
Although the present study does not address the question, other evidence suggests that thyroid hor¬ mone may be necessary for the full expression of the growth-promoting effects of GH (Salmon, 1941; Scow & Marx, 1945; Scow et al. 1949 ; Burch & Van Wyk, 1987) , and so it is possible that the differences in response of body growth to GH noted above may relate to the degree of thyroid deficiency induced in the respective experiments. In particular, some early animal studies snowed that the growth response to GH of young rats which had retained a thyroid frag¬ ment following attempted thyroidectomy at birth, was greater than the response of those animals which were shown to be totally thyroidectomized (Salmon, 1941; Scow & Marx, 1945) . Consistent with this, the dose of GH required to produce a given weight gain in young thyroidectomized rats has been reported to be 20-25 times that required to produce the same weight gain in hypophysectomized animals of about the same age (Scow et al. 1949) .
Tissue culture studies have shown that the growth response of chick cartilage to IGF-I/SMC (Burch & Van Wyk, 1987) Secondly, other studies have demonstrated effects of GH (Almazan et al. 1985) or IGF-I/SMC (Lenoir & Honegger, 1983; McMorris et al. 1986 ) on the myelinmarker enzyme CNP. The effects of IGF-I/SMC have been most marked and it is possible that the effects reported by Almazan et al. (1985) were due to IGF-I/SMC produced by the brain cells in response to added GH.
The present study, however, provides no evidence to support a mediation of the effects of thyroid hor¬ mone by IGF-I/SMC in the neonatal hypothyroid rat forebrain. Thus IGF-I/SMC concentrations in forebrain at 6 and 13 days of age were not significantly affected by hypothyroidism (Fig. 3c) , and at 20 days tended to be higher than in controls ( Fig. 3c Table 1 ). Treatment with GH, on the other hand, had no effect at all, even though plasma IGF-I/SMC levels in these animals were restored to values above those seen in T4-treated and normal con¬ trols (see Table 1 ). Although one study has produced results to the contrary (Sarlieve et al. 1983) , the lack of effect of GH in the present study is in agreement with a number of previous reports which have examined the response of various indices of myelination in hypothyroid animals (De Raveglia et al. 1974; Nogu¬ chi & Sugisaki, 1986 ).
The differences between the in-vivo and in-vitro findings are intriguing. It should be noted that the effects of thyroid hormone on IGF/SM in vitro were relatively small and variable. In addition, the precise nature of the IGF-SM was not identified, and, at higher concentrations, T3 led to decreased levels of IGF/SM. In the absence of measurements of free T3 levels in brain in the present study, however, it is diffi¬ cult to suggest a reason for this difference. With regard to the effects of GH and IGF-I/SMC, it may be relevant that systemically administered GH is unable to enter the brain of the rat (Mayberry, Van den Brande, Van Wyk & Waddell, 1971 ) and so would not itself be expected to influence brain processes in vivo. It has been suggested that GH procures any effects in the brain through the production of IGF/SM in other tissues (Almazan et al. 1985) . The presence of IGF transporter systems in brain (Pardridge, 1986 ) is consistent with this suggestion. Notwithstanding this, restoration of circulating IGF-I/SMC levels by GH in hypothyroid rats had no effect on CNP activity in brain. It may be significant that the in-vitro studies with IGF-I/SMC (Lenoir & Honegger, 1983 (Almazan et al. 1985) .
In summary, the present work confirms those limited previous observations which have shown only a small response of body weight and no significant response of myelination following GH administration in the hypothyroid infant rat. Unlike previous work, the adequacy of GH treatment to restore circulating IGF-I/SMC levels has been demonstrated so provid¬ ing strong reasons for acceptance of the negative findings.
